Search Results for "antithrombotics"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for antithrombotics. Results 41 to 46 of 46 total matches.
What About Celebrex?
The Medical Letter on Drugs and Therapeutics • Oct 25, 2004 (Issue 1194)
, and COX-2 mediated prostaglandin I
2
(prostacyclin), which is antithrombotic. Hypothetically, therefore ...
Rofecoxib (Vioxx - Merck) has been withdrawn from the market due to an increased risk of cardiovascular complications associated with its long-term use. The question remains whether all selective COX-2 inhibitors carry the same risk. Full-page advertisements in newspapers for celecoxib (Celebrex - Pfizer), the most widely used COX-2 inhibitor, assure the public that it does not.
Which Oral Anticoagulant for Atrial Fibrillation?
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016 (Issue 1492)
-to-head comparisons of the new
drugs are lacking.
1. RG Hart et al. Meta-analysis: antithrombotic ...
Direct-to-consumer advertisements continue to
urge patients who take warfarin (Coumadin, and
others) for atrial fibrillation to ask their doctors
about the benefits of one or another of the newer
oral anticoagulants.
Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018 (Issue 1537)
: Antithrombotic
Therapy and Prevention of Thrombosis, 9th ed:
American College of Chest Physicians Evidence ...
The FDA has approved betrixaban (Bevyxxa –
Portola), a once-daily, oral, direct factor Xa inhibitor,
for prophylaxis of venous thromboembolism (VTE)
in adults hospitalized for an acute medical illness
who have moderately or severely restricted mobility
and other risk factors for VTE. Betrixaban is the
first oral anticoagulant to be approved in the US for
this indication.
Drugs for Hypertriglyceridemia
The Medical Letter on Drugs and Therapeutics • Mar 04, 2013 (Issue 1411)
,
antithrombotic and lipid-modifying therapy (mainly
statins) found that addition of omega-3 fatty acids ...
Fibrates, niacin and fish oil are promoted for treatment
of hypertriglyceridemia. HMG-CoA reductase inhibitors
(statins) can lower elevated serum concentrations of
triglycerides, but less so than fibrates, niacins or fish oil.
Lifestyle changes such as weight reduction, exercise
and decreasing alcohol intake can also lower serum
triglyceride levels and should be tried first.
Antiplatelet Therapy for Patients with Stents
The Medical Letter on Drugs and Therapeutics • Aug 11, 2008 (Issue 1292)
. Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy ...
The antiplatelet agents aspirin and clopidogrel (Plavix, and others) are used in most patients undergoing percutaneous coronary intervention (PCI) to prevent stent thrombosis and to reduce the occurrence of peri-, post-procedural and late cardiovascular events. Despite a large number of randomized trials of these agents in such patients, the optimal dosage and duration of treatment with these drugs, and whether other drugs should be added, is unclear.
Drugs for Percutaneous Coronary Interventions
The Medical Letter on Drugs and Therapeutics • Dec 06, 2004 (Issue 1197)
intracoronary stenting. Circulation 1998; 98:2126.
10. STARS. A clinical trial comparing three antithrombotic ...
Percutaneous coronary intervention (PCI), such as balloon angioplasty or stent placement, predisposes to subsequent thrombosis. The current pharmacologic approach to prevention of this problem combines an anticoagulant with one or more antiplatelet drugs.